Menu
Since the 1980s, heartburn drug ranitidine, sold under the brand name Zantac and others, has been one of the most commonly prescribed medications in U.S. history.
However, in 2019, a probable human carcinogen–meaning it could cause cancer– called NDMA was detected in ranitidine products, including Zantac. Reports showed that NDMA levels in the drug could increase over time, especially when stored at higher temperatures. NDMA in ranitidine has been linked to bladder cancer, stomach cancer, and liver cancer, among others.
Ultimately, it was determined that NDMA impurities present in Zantac and other ranitidine products exceeded acceptable levels. In April 2020, the FDA requested a full market withdrawal of all ranitidine products in the United States.
Victims Have Much to Gain
Following the revelations that Zantac and other ranitidine products could be linked to cancer, ensuing lawsuits from victims who allege using the drug caused them to develop cancer come with a unique advantage.
Zantac lawsuits do not allege ranitidine, the main ingredient of Zantac, causes cancer. The issue is that, at a molecular level, ranitidine is capable of producing NDMA, which is universally acknowledged to carry cancer risk. This is the legal approach being taken, and it is backed by the FDA.
The Early Stages of Litigation
The revelations about Zantac and ranitidine are relatively new, but litigation is pushing forward at high speed. There have been no settlements yet, but as of February 2022, GlaxoSmithKline, Pfizer, Boehringer Ingelheim, and Sanofi have all been named as defendants in a federal multidistrict litigation in the Southern District of Florida.
Duncan|Stubbs is leveraging all of its resources to ensure Zantac lawsuit plaintiffs secure the compensation they are owed. As we speak, highly specialized attorneys are building cases based on clients’ objectives and ensuring they align with a winning legal strategy.
As it stands, victims who come forward now are in a strong position to win their case. With the FDA’s removal of Zantac from the market and overwhelming evidence supporting plaintiffs’ cases, we are confident that these drug manufacturers will be held accountable.
Duncan|Stubbs is currently accepting new cases from victims who took brand name Zantac at this time. We vow to fight on your behalf until the highest settlement amount is recovered. If we do not win, we will not charge for our services.
Generic ranitidine defendants are excluded from legal action at this time, per an order outside of our firm’s control. However, the order is pending appeal and we provide any updates as soon as we know the result.
How can we help?